Your browser is no longer supported. Please, upgrade your browser.
Settings
BCYC [NASD]
Bicycle Therapeutics plc
Index- P/E- EPS (ttm)-2.89 Insider Own0.80% Shs Outstand25.04M Perf Week-6.49%
Market Cap1.61B Forward P/E- EPS next Y-2.75 Insider Trans-58.25% Shs Float4.33M Perf Month1.90%
Income-66.20M PEG- EPS next Q-0.72 Inst Own58.90% Short Float11.10% Perf Quarter64.26%
Sales11.80M P/S136.64 EPS this Y3.90% Inst Trans11.90% Short Ratio1.40 Perf Half Y85.08%
Book/sh6.82 P/B8.01 EPS next Y-7.30% ROA-29.70% Target Price72.50 Perf Year175.76%
Cash/sh8.79 P/C6.21 EPS next 5Y- ROE-48.10% 52W Range17.95 - 62.08 Perf YTD204.18%
Dividend- P/FCF- EPS past 5Y- ROI-46.60% 52W High-11.96% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low204.46% ATR3.14
Employees87 Current Ratio9.00 Sales Q/Q13.20% Oper. Margin- RSI (14)46.95 Volatility5.91% 5.63%
OptionableYes Debt/Eq0.17 EPS Q/Q-12.30% Profit Margin- Rel Volume0.35 Prev Close54.60
ShortableYes LT Debt/Eq0.17 EarningsNov 04 Payout- Avg Volume344.47K Price54.65
Recom1.70 SMA20-4.05% SMA504.43% SMA20051.91% Volume48,534 Change0.09%
Sep-30-21Initiated B. Riley Securities Buy $56
Apr-20-21Initiated JMP Securities Mkt Outperform $53
Oct-12-20Initiated Cantor Fitzgerald Overweight $30
Jun-12-20Initiated Oppenheimer Outperform
Apr-17-20Initiated H.C. Wainwright Buy $25
Nov-14-19Initiated ROTH Capital Buy $17
Sep-11-19Upgrade Goldman Neutral → Buy $14
Jun-17-19Initiated Piper Jaffray Overweight $20
Jun-17-19Initiated Jefferies Buy $22
Jun-17-19Initiated Goldman Neutral $14
Jun-17-19Initiated Canaccord Genuity Buy $22
Nov-11-21 07:00AM  
Nov-09-21 08:00AM  
Nov-05-21 07:02AM  
Nov-04-21 06:59AM  
06:45AM  
Nov-02-21 07:10AM  
Oct-26-21 07:00AM  
Oct-18-21 09:11AM  
07:00AM  
Oct-13-21 12:38AM  
Oct-12-21 06:57AM  
Oct-07-21 12:50PM  
Oct-04-21 05:51AM  
Sep-30-21 04:30PM  
Sep-01-21 07:00AM  
Aug-07-21 03:08AM  
Aug-05-21 06:59AM  
Jul-29-21 11:16AM  
Jul-28-21 10:00AM  
Jul-23-21 08:50AM  
Jul-20-21 10:28AM  
08:59AM  
Jul-14-21 09:55AM  
Jul-13-21 08:06AM  
06:59AM  
06:59AM  
Jul-07-21 08:50AM  
01:56AM  
Jun-15-21 04:30PM  
May-27-21 07:00AM  
May-08-21 03:17AM  
May-06-21 07:00AM  
Apr-10-21 08:30AM  
Apr-09-21 07:32AM  
Mar-30-21 07:00AM  
Mar-18-21 08:34AM  
Mar-11-21 04:05PM  
07:00AM  
Mar-07-21 11:11PM  
Jan-26-21 07:20AM  
Jan-14-21 07:00AM  
Jan-06-21 11:58PM  
Dec-09-20 01:32PM  
Nov-24-20 06:59AM  
Nov-20-20 04:05PM  
Nov-12-20 04:01PM  
Nov-09-20 06:59AM  
Nov-08-20 07:17AM  
Nov-05-20 06:59AM  
Oct-21-20 06:59AM  
Oct-14-20 05:08PM  
Oct-01-20 08:06AM  
Sep-19-20 08:03AM  
Sep-18-20 07:30AM  
Sep-14-20 06:59AM  
Sep-10-20 04:05PM  
Sep-03-20 06:59AM  
Sep-02-20 06:59AM  
Sep-01-20 06:59AM  
Aug-06-20 08:03AM  
Aug-05-20 04:05PM  
06:59AM  
Jun-24-20 08:37AM  
Jun-23-20 06:59AM  
Jun-22-20 06:59AM  
Jun-13-20 07:56AM  
Jun-12-20 06:46PM  
May-27-20 06:59AM  
May-15-20 06:59AM  
May-13-20 05:09PM  
May-12-20 06:59AM  
May-08-20 09:32AM  
May-07-20 06:59AM  
May-06-20 06:59AM  
May-05-20 06:59AM  
Apr-23-20 06:59AM  
Apr-08-20 07:16AM  
Apr-07-20 06:59AM  
Apr-06-20 06:59AM  
Mar-31-20 07:22AM  
Mar-30-20 11:30AM  
Mar-17-20 06:45AM  
Mar-16-20 08:38AM  
Mar-13-20 12:00PM  
11:30AM  
10:18AM  
Mar-10-20 06:59AM  
Feb-25-20 06:59AM  
Jan-07-20 07:00AM  
Dec-22-19 06:09PM  
Nov-26-19 07:00AM  
07:00AM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 08:14AM  
Oct-31-19 07:00AM  
Oct-29-19 07:00AM  
Oct-22-19 03:00AM  
Oct-16-19 04:33PM  
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee KevinChief Executive OfficerOct 18Sale60.00492,940225,085Oct 18 06:22 PM
Lee KevinChief Executive OfficerOct 15Sale60.0532019,216225,134Oct 18 06:22 PM
Lee KevinChief Executive OfficerOct 14Sale60.004,631277,860225,454Oct 18 06:22 PM
Lee KevinChief Executive OfficerOct 11Sale53.885,000269,388230,085Oct 13 05:28 PM
Keen NicholasChief Scientific OfficerOct 05Sale45.102,17898,2280Oct 05 04:16 PM
Keen NicholasChief Scientific OfficerOct 01Sale45.001,18853,4602,178Oct 05 04:16 PM
Smethurst DominicChief Medical OfficerSep 23Option Exercise18.556,000111,3006,000Sep 27 04:53 PM
Keen NicholasChief Scientific OfficerSep 16Sale45.011,95587,9953,366Sep 17 04:47 PM
Keen NicholasChief Scientific OfficerSep 15Sale45.003,000135,0005,321Sep 17 04:47 PM
Kalowski LeePresident and CFOSep 02Option Exercise9.8210,00098,20010,000Sep 03 04:49 PM
Kalowski LeePresident and CFOSep 02Sale40.0010,000400,0000Sep 03 04:49 PM
Keen NicholasChief Scientific OfficerSep 02Sale40.0010,000400,0008,321Sep 03 04:47 PM
Lee KevinChief Executive OfficerSep 02Sale40.005,000200,000235,085Sep 03 04:46 PM
Lee KevinChief Executive OfficerSep 01Option Exercise14.0022,890320,460267,170Sep 03 04:46 PM
Lee KevinChief Executive OfficerSep 01Sale37.2127,0851,007,897240,085Sep 03 04:46 PM
Lee KevinChief Executive OfficerAug 31Option Exercise14.0010,420145,880255,505Aug 31 05:29 PM
Lee KevinChief Executive OfficerAug 31Sale36.3311,225407,763244,280Aug 31 05:29 PM
Kalowski LeePresident and CFOAug 27Option Exercise8.737,95069,4047,950Aug 27 06:31 PM
Lee KevinChief Executive OfficerAug 27Option Exercise14.001,80825,312246,893Aug 31 05:29 PM
Lee KevinChief Executive OfficerAug 27Sale36.021,80865,124245,085Aug 31 05:29 PM
Kalowski LeePresident and CFOAug 27Sale35.157,950279,4420Aug 27 06:31 PM
Kalowski LeePresident and CFOAug 26Option Exercise8.765504,818550Aug 27 06:31 PM
Kalowski LeePresident and CFOAug 26Sale35.0455019,2720Aug 27 06:31 PM
Kalowski LeePresident and CFOAug 23Option Exercise1.607,50012,0007,500Aug 25 05:45 PM
Kalowski LeePresident and CFOAug 23Sale33.027,500247,6500Aug 25 05:45 PM
Kalowski LeePresident and CFOJul 29Option Exercise1.6312,50020,37512,500Jul 30 06:21 PM
Kalowski LeePresident and CFOJul 29Sale31.5112,500393,8230Jul 30 06:21 PM
Lee KevinChief Executive OfficerJul 26Option Exercise14.001001,400245,185Jul 27 07:08 PM
Lee KevinChief Executive OfficerJul 26Sale36.001003,600245,085Jul 27 07:08 PM
Lee KevinChief Executive OfficerJul 23Option Exercise14.004,78266,948249,867Jul 27 07:08 PM
Lee KevinChief Executive OfficerJul 23Sale36.024,782172,248245,085Jul 27 07:08 PM
Lee KevinChief Executive OfficerJul 16Option Exercise14.006098,526245,694Jul 16 06:27 PM
Lee KevinChief Executive OfficerJul 16Sale34.0060920,706245,085Jul 16 06:27 PM
Lee KevinChief Executive OfficerJul 15Option Exercise14.0021,970307,580267,055Jul 16 06:27 PM
Lee KevinChief Executive OfficerJul 15Sale34.2821,970753,132245,085Jul 16 06:27 PM
Lee KevinChief Executive OfficerJul 14Option Exercise14.008,331116,634259,550Jul 14 06:47 PM
BINGHAM KATEDirectorJul 14Sale34.0144,2951,506,36738,708Jul 15 07:03 PM
Lee KevinChief Executive OfficerJul 14Sale34.3414,465496,726245,085Jul 14 06:47 PM
Keen NicholasChief Scientific OfficerJul 14Sale35.0010,000350,00018,321Jul 16 06:27 PM
Lee KevinChief Executive OfficerJul 13Option Exercise14.0035,446496,244290,180Jul 14 06:47 PM
Crockett NigelChief Business OfficerJul 13Option Exercise11.8472,701860,43372,701Jul 14 06:47 PM
BINGHAM KATEDirectorJul 13Sale33.5060020,10039,625Jul 15 07:03 PM
Crockett NigelChief Business OfficerJul 13Sale32.4472,7012,358,3620Jul 14 06:47 PM
Lee KevinChief Executive OfficerJul 13Sale32.9738,9611,284,680251,219Jul 14 06:47 PM
Lee KevinChief Executive OfficerJul 12Option Exercise14.001,93627,104256,670Jul 14 06:47 PM
Crockett NigelChief Business OfficerJul 12Option Exercise11.727,02882,3807,028Jul 14 06:47 PM
Crockett NigelChief Business OfficerJul 12Sale32.037,028225,1070Jul 14 06:47 PM
Lee KevinChief Executive OfficerJul 12Sale32.041,93662,029254,734Jul 14 06:47 PM
Crockett NigelChief Business OfficerJul 06Option Exercise9.822712,661271Jul 08 05:22 PM
Crockett NigelChief Business OfficerJul 06Sale32.002718,6720Jul 08 05:22 PM
Lee KevinChief Executive OfficerMay 07Option Exercise14.005,60478,456260,338May 10 05:43 PM
Lee KevinChief Executive OfficerMay 07Sale32.235,604180,617254,734May 10 05:43 PM
Lee KevinChief Executive OfficerMay 06Option Exercise14.001,71624,024256,450May 10 05:43 PM
Lee KevinChief Executive OfficerMay 06Sale32.141,71655,152254,734May 10 05:43 PM
Lee KevinChief Executive OfficerMay 04Option Exercise14.0089712,558255,631May 05 04:40 PM
Lee KevinChief Executive OfficerMay 04Sale32.0389728,731254,734May 05 04:40 PM
Lee KevinChief Executive OfficerMay 03Option Exercise14.003,39147,474258,125May 05 04:40 PM
Lee KevinChief Executive OfficerMay 03Sale32.163,391109,055254,734May 05 04:40 PM
Lee KevinChief Executive OfficerApr 30Option Exercise14.0030,406425,684285,140Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 30Sale30.7630,406935,204254,734Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 29Option Exercise14.006,01884,252260,752Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 29Sale30.516,018183,612254,734Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 28Option Exercise14.0022,495314,930277,229Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 28Sale31.0822,495699,172254,734Apr 30 06:14 PM
Lee KevinChief Executive OfficerApr 27Option Exercise14.006,63692,904261,370Apr 28 04:45 PM
Lee KevinChief Executive OfficerApr 27Sale30.706,636203,728254,734Apr 28 04:45 PM
Lee KevinChief Executive OfficerApr 26Option Exercise14.0014,545203,630273,345Apr 28 04:45 PM
Lee KevinChief Executive OfficerApr 26Sale31.2818,611582,144254,734Apr 28 04:45 PM
Legault PierreDirectorApr 08Option Exercise8.7424,838217,08424,838Apr 09 04:36 PM
Legault PierreDirectorApr 08Sale31.7124,838787,5880Apr 09 04:36 PM
Legault PierreDirectorApr 05Option Exercise8.831621,430162Apr 07 07:22 PM
Legault PierreDirectorApr 05Sale31.071625,0330Apr 07 07:22 PM
Legault PierreDirectorMar 31Option Exercise8.7810,00087,80010,000Apr 02 04:44 PM
Legault PierreDirectorMar 31Sale30.0010,000300,0000Apr 02 04:44 PM
Keen NicholasChief Scientific OfficerMar 31Sale30.0010,000300,00028,321Apr 02 04:45 PM
Legault PierreDirectorMar 17Option Exercise8.857,78468,8887,784Mar 19 04:48 PM
Legault PierreDirectorMar 17Sale29.007,784225,7360Mar 19 04:48 PM
Keen NicholasChief Scientific OfficerMar 15Sale28.002176,07638,321Mar 16 07:41 PM
Legault PierreDirectorMar 12Option Exercise8.862,21619,6342,216Mar 16 07:42 PM
Legault PierreDirectorMar 12Sale29.002,21664,2640Mar 16 07:42 PM
Keen NicholasChief Scientific OfficerMar 12Sale28.509,783278,76738,538Mar 16 07:41 PM
Lee KevinChief Executive OfficerFeb 05Sale31.001003,100258,800Feb 09 05:28 PM
Lee KevinChief Executive OfficerJan 20Sale31.881,18537,779258,900Jan 21 04:34 PM
Kalowski LeePresident and CFOJan 19Option Exercise1.5915,00023,85015,000Jan 21 04:29 PM
Lee KevinChief Executive OfficerJan 19Sale29.265,000146,290260,085Jan 21 04:34 PM
Kalowski LeePresident and CFOJan 19Sale30.0015,000450,0000Jan 21 04:29 PM
Lee KevinChief Executive OfficerJan 15Sale27.015,000135,050265,085Jan 15 04:40 PM
Kalowski LeePresident and CFOJan 14Option Exercise1.6010,00016,00010,000Jan 15 04:44 PM
Kalowski LeePresident and CFOJan 14Sale25.0010,000250,0000Jan 15 04:44 PM
Lee KevinChief Executive OfficerJan 14Sale25.005,000125,000270,085Jan 15 04:40 PM
Kalowski LeePresident and CFODec 01Option Exercise1.567,50011,7007,500Dec 03 08:53 PM
Kalowski LeePresident and CFODec 01Sale22.507,500168,7500Dec 03 08:53 PM